DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

First Quarterly Performance Report Released for the 2019-2020 Fiscal Year
December 16, 2019

The Quarterly Performance Report for the first quarter of the 2019-2020 fiscal year is now available online. Continue reading


Hepatitis A Public Health Emergency
December 3, 2019

Florida, like other parts of the United States, is experiencing a Public Health Emergency as a result of Hepatitis A Virus (HAV). Click here for more information. Continue reading